RxDoctor Payments Data

Ann Wieman, DPM

Podiatrist · Warrenton, MONPI 1366557290

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 68.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $547 and has fallen 55.9% since, to $241 in 2025.

$1,729in general payments, 2019–2025

Across 94 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$1K
  • Kerecis Limited$115
  • Koya Medical, Inc.$101
  • Bioventus LLC$48
  • Zimvie Inc.$45
  • ETS Wound Care LLC$45
  • plus $194 from 7 others

What the payments were for

  • Food & beverage$1,729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,729 in reported general payments places this provider in the 55th percentile of 105 podiatrist providers in Missouri.

See all podiatrist providers in Missouri

Medicare billing

Part B allowed, 2024
$48,134
Medicare patients
311
Services billed
1,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl33$732
Ciclopirox31$692
Mupirocin20$332
Ketoconazole15$184
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$135
Doxycycline Hyclate15$133
Meloxicam11$48
Cephalexin13$32

Paid to pharmacies, not to this prescriber.

Other podiatrist in Warrenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →